New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:00 EDTBDSI, ENDPBDSI updates Phase lll clinical trials for BEMA Buprenorphine
BDSI said in a press release that significant progress was made in the development of BioDelivery Sciences International, BDSI's (BDSI), two buprenorphine-containing products with the initiation, in partnership with Endo Health Solutions (ENDP) of two Phase 3 pivotal trials with BEMA Buprenorphine for the treatment of chronic pain. BDSI also completed key bioavailability and safety studies with BUNAVAIL (formerly BEMA Buprenorphine/Naloxone or BNX) for the treatment of opioid dependence. Phase 3 clinical trials for BEMA Buprenorphine in conjunction with Endo to complete in late 2013 or early 2014
News For BDSI;ENDP From The Last 14 Days
Check below for free stories on BDSI;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTENDPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 14, 2014
09:31 EDTENDPEndo upgraded to Conviction Buy from Buy at Goldman
July 11, 2014
11:19 EDTBDSIOptions with decreasing implied volatility: BDSI CWH INFY MONT
Subscribe for More Information
08:05 EDTENDPEndo recommended ahead of Q2 report at Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use